J1325 — Injection, epoprostenol, 0.5 mg
J1325 is a HCPCS Level II code for injection, epoprostenol, 0.5 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
Medically Unlikely Edits — units per day
The most units of J1325 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 1 unit MAI 3 — Date of Service Edit: Clinical · Clinical: Data
- outpatient
- 18 units MAI 3 — Date of Service Edit: Clinical · Clinical: Data
- DME supplier
- 810 units MAI 3 — Date of Service Edit: Clinical · Clinical: Data
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute — no documentation overrides it. CMS MUE 2026Q3.
The CMS record for J1325
- Long descriptor
- Injection, epoprostenol, 0.5 mg
- Short descriptor
- Epoprostenol injection
- Added
- January 1, 1998
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J1325
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J1325 is not quite right, the correct code is very often within a few positions of it.
- J1305Injection, evinacumab-dgnb, 5mg
- J1306Injection, inclisiran, 1 mg
- J1307Injection, crovalimab-akkz, 10 mg
- J1308Injection, famotidine, 0.25 mg
- J1320Injection, amitriptyline hcl, up to 20 mg
- J1322Injection, elosulfase alfa, 1 mg
- J1323Injection, elranatamab-bcmm, 1 mg
- J1324Injection, enfuvirtide, 1 mg
- J1326Injection, zolbetuximab-clzb, 2 mg
- J1327Injection, eptifibatide, 5 mg
- J1330Injection, ergonovine maleate, up to 0.2 mgterminated
- J1335Injection, ertapenem sodium, 500 mg
- J1364Injection, erythromycin lactobionate, per 500 mg
- J1370Injection, esomeprazole sodium, 1 mg
- J1380Injection, estradiol valerate, up to 10 mg
- J1410Injection, estrogen conjugated, per 25 mg
Questions about J1325
What is HCPCS code J1325?
J1325 is a HCPCS Level II code for injection, epoprostenol, 0.5 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J1325?
The CMS HCPCS file marks J1325 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
How is J1325 paid under the physician fee schedule?
J1325 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).